Abstract: Combinations of fructose-and fat-rich diets in experimental animals can model the human metabolic syndrome (MS). In rats, the increase in blood pressure (BP) after diet manipulation is sex related and highly dependent on testosterone secretion. However, the extent of the impact of diet on rodent hypophysial-testicular axis remains undefined. In the present study, rats drinking a 10% fructose solution or fed a high-fat (35%) diet for 10 weeks had higher plasma levels of luteinizing hormone (LH) and lower plasma levels of testosterone, without significant changes in circulating follicle-stimulating hormone or the weight of most reproductive organs. Diet manipulation brought about a significant increase in body weight, systolic BP, area under the curve (AUC) of glycemia after an intraperitoneal glucose tolerance test (IPGTT), and plasma low-density lipoprotein cholesterol, cholesterol, triglycerides, and uric acid levels. The concomitant administration of melatonin (25 μg/mL of drinking water) normalized the abnormally high LH levels but did not affect the inhibited testosterone secretion found in fructose-or high-fat-fed rats. Rather, melatonin per se inhibited testosterone secretion. Melatonin significantly blunted the body weight and systolic BP increase, the increase in the AUC of glycemia after an IPGTT, and the changes in circulating lipid profile and uric acid found in both MS models. The results are compatible with a primary inhibition of testicular function in diet-induced MS in rats and with the partial effectiveness of melatonin to counteract the metabolic but not the testicular sequelae of rodent MS.
Introduction
The cluster of cardiovascular disease risk factors including obesity, hypertension, hyperinsulinemia, glucose intolerance, and dyslipidemia is known as the metabolic syndrome (MS) [1] [2] [3] [4] . MS is a major clinical challenge with a prevalence of 15%-30% depending on the world region considered, and its presence increases overall cardiovascular mortality by 1.5-to 2.5-fold. Indeed, MS and the aging of the population are the two greatest public health concerns of the 21st century [5, 6] . Each of these trends has important effects on body composition, functional disability, and mortality. An important change in body composition with aging is the increase in fat mass and visceral fat [7] , which increases susceptibility to MS and cardiovascular disease. Adipocytes actively secrete leptin and proinflammatory cytokines and activate a vicious cycle that leads to additional weight gain largely in the form of fat [8, 9] .
One of the factors that contribute to the increase in MS incidence is poor eating habits, which are mainly characterized by a large increase in fructose and fat consumption [1] [2] [3] [4] . In the case of fructose, an impending increase in intake, primarily in the form of sucrose (which contains 50% fructose) and corn syrup (55% fructose content), has been documented in the last 25 years [4] . High fructose intake has been commonly modeled in rats [10] and lately in non-human primates [11] . In both types of animals, fructose feeding induces hypertension, hyperinsulinemia, insulin resistance, and hypertriglyceridemia [12] . In the case of high-fat diets, they have been used for decades to model obesity, dyslipidemia, and insulin resistance in rodents [13] .
The increase in body weight after a high-fructose or high-fat diet is accompanied by increased systolic blood pressure (BP) and endothelial dysfunction [14] [15] [16] . This effect is sex related and needs the presence of testosterone to become apparent [17] . Meanwhile, obesity is associated with an altered hormonal milieu that can affect the reproductive system, as shown by the association of increased body mass index (BMI) in men with low testosterone and sex hormone-binding globulin levels [18] .
In rat models of diet-induced MS, diet manipulation brought about a significant decrease in total plasma testosterone levels [19] [20] [21] and a loss of correlation between circulating testosterone and luteinizing hormone (LH) levels [19] . Other studies, however, failed to observe such an effect of diet on testosterone secretion [22, 23] . The aim of the present experiments was to examine the impact of diet on the activity of the hypophysial-testicular axis of rats after being given 10% fructose as a drinking solution or a high (35%)-fat diet for 10 weeks. The possible corrective effect of melatonin on MS sequelae was examined because among several substances with the capacity to curtail MS, melatonin has received increasing attention due to its very low or absent toxicity, making it potentially appropriate for human use [2, [24] [25] [26] [27] [28] .
Materials and methods

Animals and experimental design
Male Wistar rats (60 days old) were kept under standard conditions of controlled light (12:12-h light/dark schedule; lights on at 08:00 h) and temperature (22°C ± 2°C).
In the first experiment, the effect of fructose or high-fat administration on plasma LH, testosterone, and follicle-stimulating hormone (FSH) levels and on reproductive organ weight was measured. In addition, a number of somatic and metabolic components were used clinically to monitor MS, i.e., body weight increase, systolic BP, intraperitoneal glucose tolerance test (IPGTT), and several circulating analytes including triglycerides, total cholesterol, high-and low-density lipoprotein cholesterol (HDL-c and LDL-c, respectively), creatinine, urea, and uric acid were also measured. For the fructose experiment groups, eight rats had ad libitum access for 10 weeks to one of the following drinking solutions: (i) a 10% fructose solution (in which fructose accounted for 48%-57% of total caloric intake [29] ); (ii) tap water. Normal rat chow was given ad libitum; it contained 3% fat, 16% protein, and 60% carbohydrate (mainly as starch with < 0.4% fructose), providing a total caloric content of 2.9 kcal/g. For the high-fat-diet experiment groups, eight rats had ad libitum access for 10 weeks to tap water and one of the following diets: (i) highfat chow; (ii) normal rat chow. The high (35%)-fat chow contained 35% carbohydrates and 20% proteins, providing a total caloric content of 5.4 kcal/g, whereas the normal chow provided a total caloric content of 2.9 kcal/g.
In the second experiment, the efficacy of melatonin to counteract the hypophysial-testicular sequelae of MS seen in rats fed a 10% fructose solution was examined. Animals were randomly divided into four groups (n = 8/group) and had free access to chow and one of the following drinking solutions for 10 weeks: (i) 10% fructose; (ii) 10% fructose plus 25 μg/mL of melatonin; (iii) 25 μg/mL of melatonin; (iv) tap water. Because ethanol was used as a melatonin vehicle, drinking solutions in groups i and iv were added 0.015% ethanol. The activity of the hypophysialtesticular axis and the somatic and metabolic components of MS were measured as in experiment 1.
The aim of experiment 3 was to examine the efficacy of melatonin to counteract the changes in the hypophysial-testicular axis seen in rats fed a high-fat diet. Animals were randomly divided into four groups (n = 8/group) and had free access to high-fat or control chow and one of the following drinking solutions for 10 weeks: (i) tap water; (ii) 25 μg/mL of melatonin. In group i, 0.015% ethanol was added to the drinking solutions. The activity of the hypophysial-testicular axis and the somatic and metabolic components of MS were measured as in experiment 1.
Chow and water consumption were measured weekly. The caloric intake for fructose-fed rats was calculated as the sum of calories ingested as food based on 2.9 kcal/g of chow consumed, with each ingested gram of fructose corresponding to 4.0 kcal. The caloric intake for high-fat-fed rats was calculated as the sum of calories ingested as food based on 5.4 kcal/g of chow consumed.
The daily melatonin dosage used varied from 1.9 to 3.2 mg/kg, with the higher values corresponding to rats drinking fructose. The human equivalence dose, calculated using the body surface area normalization method [30] , was 0.31-0.52 mg/kg (i.e., 21-35 mg/day for a 70-kg adult).
BP measurement
Systolic BP was measured using a manometer-tachometer (Rat Tail NIBP System; ADInstruments, Sydney, NSW, Australia) with an inflatable tail-cuff connected to a MLT844 Physiological Pressure Transducer (ADInstruments, Sydney, NSW, Australia) and PowerLab data acquisition unit (ADInstruments, Sydney, NSW, Australia). Rats were placed in a plastic holder mounted on a thermostatically controlled warm plate that was maintained at 35°C during measurements. The average value from three BP readings (which differed by no more than 2 mm Hg) was determined for each animal after they became acclimated to the environment. All BP measurements were done between 09:00 and 12:00 h.
Biochemical assays
The IPGTT was performed at 09:00 h after a 2-h fast. Rats were anesthetized, and after the collection of an unchallenged sample (time 0), a glucose solution of 2 g/kg body weight was intraperitoneally administered. During the test, blood was collected by lateral tail bleeding at 30, 60, and 120 min after glucose administration to measure glucose concentration. Glycemia was measured using an Accu-Check Compact kit (Roche Diagnostics, Indianapolis, IN, USA). The area under the curve (AUC) for glycemia was calculated using the trapezoidal method test [31] .
The rats were euthanized by decapitation under conditions of minimal stress. All experiments were conducted in accordance with the guidelines of the International Council for Laboratory Animal Science. Trunk blood was collected, and plasma samples were obtained by centrifugation of blood at 1500 g for 15 min. EDTA (6 g/100 mL) was used as anticoagulant. Samples were stored at -70°C until further analysis.
Plasma LH and FSH levels were measured by a homologousspecific double antibody radioimmunoassay (RIA), using materials kindly supplied by the National Hormone and Pituitary Program of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and by Dr. A. Parlow (Harbor UCLA Medical Center, Torrance, CA, USA), as described elsewhere [19] . The intra-and inter-assay coefficients of variation were 6% and 8%, respectively. The sensitivity of the RIA was 97.5 pg/mL using the NIDDK rat appropriate standard. Plasma testosterone concentration was measured by a specific RIA obtained from DIAsource ImmunoAssays (Nivelles, Belgium). The intra-and inter-assay coefficients of variation were 6% and 8%, respectively. The sensitivity of the RIA was 0.1 ng of testo sterone/mL.
The plasma lipid profile was determined by measuring the trigly ceride, total cholesterol, HDL-c, and LDL-c content using commercially available reagent kits per manufacturer instructions (BioSystems, Buenos Aires, Argentina). Creatinine, urea, and uric acid were measured by standard enzymatic procedures (BioSystems, Buenos Aires, Argentina).
Statistical analysis
After verifying the normality of distribution of data, the statistical analysis of the results was performed by a one-or two-way factorial analysis of variance (ANOVA) followed by Bonferroni multiple comparison test or Student's t-test, as stated, with statistical significance at p < 0.05.
Results
In the fructose studies, chow consumption was similar for controls (16 ± 2 g/rat/day) and fructose-overloaded rats (15 ± 2 g/rat/day). Water consumption was 25 ± 4 mL/rat/day (controls) and 39 ± 5 mL/rat/day (10% fructose) (p < 0.02, Student's t-test). Therefore, the individual total caloric intake was 44 ± 3 kcal/day (controls) and 61 ± 4 kcal/day (fructose) (p < 0.03, Student's t-test).
In high-fat-diet studies, individual daily chow and water consumption were similar for controls (17 ± 3 g and 27 ± 3 mL) and high-fat-fed rats (16 ± 3 g and 29 ± 2 mL). Individual total caloric intake (kcal/day) was 44 ± 3 (controls) and 71 ± 4 (high-fat diet) (p < 0.01, Student's t-test). Melatonin administration did not significantly affect chow or water consumption.
The results of experiment 1 are summarized in Tables 1 and 2 . The administration of a 10% fructose drinking solution or a high-fat chow to rats brought about significant increases in body weight, systolic BP, and AUC of glycemia after an IPGTT (Table 1) . Rats fed with fructose or a high-fat diet had significantly higher plasma levels of LH and significantly lower plasma levels of testosterone, without significant changes in plasma FSH. Only the weight of the seminal vesicles of fructose-fed rats was significantly higher than that of controls ( Table 1 ). The experimental manipulation of diet in rats brought about significant changes in circulating analytes in fructoseand high-fat-fed rats, with increases of LDL-c, cholesterol, triglycerides, and uric acid ( Table 2) .
The effectiveness of melatonin to counteract the hypophysial-testicular sequelae in the fructose-induced MS is Table 1 Changes in body weight, systolic BP, IPGTT, plasma levels of reproductive hormones, and testicular, epididymal, and seminal vesicle weight in rats receiving either a 10% fructose drinking solution or tap water (fructose study) or a high-fat or normal diet (high-fat study) for 10 weeks.
Fructose study
High-fat study summarized in Figure 1 and Table 3 . Melatonin administration normalized the abnormally high LH levels but did not affect the inhibited testosterone secretion found in fructose-fed rats. Rather, a significant inhibition of testosterone levels was found in rats administered with melatonin alone (Figure 1 ). Neither testicular nor epididymal weight was affected by the treatment, but the weight of the seminal vesicle was significantly augmented in rats drinking the 10% fructose solution (Figure 1 ). Melatonin significantly blunted the body weight and systolic BP increase found in rats drinking 10% fructose solution ( Table 3 ). The increase in the AUC of glycemia after an IPGTT found in fructose-fed rats as well as the changes in the lipid profile and uric acid levels was also prevented by melatonin (Table 3) . When analyzed as a main factor in a factorial ANOVA, melatonin significantly decreased the uric acid levels (p < 0.01).
The efficacy of melatonin to counteract the changes in the hypophysial-testicular axis and the somatic and metabolic changes seen in rats fed a high-fat diet is summarized in Figure 2 and Table 4 . Diet manipulation produced a significant inhibition of testosterone secretion and a significant stimulation of LH release without effects on FSH release (Figure 2 ). Melatonin administration normalized the abnormally high LH levels without affecting the inhibited testosterone secretion found in high-fat-fed rats. A significant inhibition of testosterone levels was found in rats administered with melatonin alone (Figure 2) . None of the treatments affected the testicular, epididymal, or seminal vesicle weight.
Rats fed with a high-fat diet showed significantly higher body weights and systolic BP after 10 weeks. Melatonin effectively counteracted these changes (Table 4) . Additionally, in high-fat-fed rats, circulating LDL-c, cholesterol, and triglyceride concentrations were significantly augmented -melatonin being effective in counteracting the observed changes in the lipid profile. Melatonin did not affect the increase in plasma HDL-c found in highfat-fed rats or modified the circulating lipid profile when given alone (Table 4) . Melatonin prevented the increase in uric acid found in high-fat-fed rats, and when analyzed as a main factor in a factorial ANOVA, melatonin significantly decreased the uric acid levels (p < 0.01) ( Table 4) .
Discussion
Overweight and insulin resistance, which are paramount components of MS, affect the endocrine system, alter the hypothalamo-hypophysial-gonadal hormonal axis, and depress testosterone secretion [32] . In a meta-analysis of clinical studies on the effect of BMI on testicular function [18] , 18 of 20 studies measuring testosterone reported negative relationships between BMI and circulating testosterone. Circulating total testosterone, in particular, free testosterone, negatively correlated with BMI [18] . In rodents, a decrease in plasma testosterone has been reported in experiments involving diet-induced models of MS [19] [20] [21] , but not in all cases [22, 23] .
Our foregoing results indicate that rats drinking a 10% fructose solution or fed a high-fat diet for 10 weeks had higher plasma levels of LH and lower plasma levels of testosterone, without significant changes in plasma FSH, thus indicating a primary effect of diet on testosterone production at the testicular level. This endocrine profile came along with the expected alterations of the experimental MS induced, i.e., significant increases in body weight and systolic BP, impaired glucose tolerance, and increased circulating levels of LDL-c, cholesterol, triglycerides, and uric acid. Endothelial dysfunction and increased BP following insulin resistance play an important role in the development of secondary cardiovascular complications in MS.
The presence of testosterone, possibly via the regulation of the synthesis of vasoconstrictor eicosanoids, is essential for the development of endothelial dysfunction and Figure 2 Effect of melatonin on plasma LH, FSH, and testosterone levels and on reproductive organ weight in rats fed a high-fat diet. Hormone levels were determined by specific RIA as described in Methods. Data are shown as means ± SEM (n = 8/group). Letters indicate significant differences between the experimental groups after a one-way ANOVA followed by a post hoc Bonferroni's test: increased BP [14] [15] [16] 22] . Moreover, testosterone treatment of fructose-fed female rats increased BP [17] . There is also information that a similar testosterone effect is seen in high-fat-fed rats [33] . Because gonadectomy was effective in preventing endothelial dysfunction and increased BP in fructose-fed male rats [14] [15] [16] 22] , the low amounts of testosterone secreted after diet manipulation in the two models of MS examined herein are presumably sufficient to provoke the vascular changes typically reported in these animals. Further studies using gonadectomized male rats could be useful to define this point, particularly in the case of high-fat-fed rats in which such information is lacking.
In a previous study, one of us (D.P.C.) reported a significant decrease in total plasma testosterone levels and a loss of correlation between testosterone with circulating LH levels in high-fat-diet-fed rats [19] , findings that were coincident with other published observations [20, 21] . Because saturated fatty acid treatment decreases LHstimulated adenylate cyclase activity [34] and testosterone levels [35] in rat testes and induces apoptosis of Leydig cells [36] , the previous and present results are compatible with a deleterious effect of high-fat diet on testicular function.
Among the several substances that can curtail MS, melatonin has received increasing attention because of its very low or absent toxicity, making it potentially appropriate for human use. A number of studies indicate that melatonin has the ability to reduce type 2 diabetes and liver steatosis (for references, see [37] ). In addition, melatonin treatment induces regeneration/proliferation of β-cells in the pancreas, which leads to a decrement in blood glucose in streptozotocin-induced type 1 diabetic rats [38] . Loss of circulating melatonin via pinealectomy results in marked hyperinsulinemia and accumulation of triglycerides in the liver [39] . Long-term administration of melatonin improves lipid metabolism in type 2 diabetic rats through the amelioration of insulin resistance [40] .
In high-fat/high-sucrose-fed rats, intraperitoneal injection of 4 mg/kg melatonin every morning for 8 weeks, starting after 20 weeks of feeding, led to weight gain inhibition together with improved insulin sensitivity [41] . Rats fed a diet containing 60% fructose exhibited an inhibition of melatonin secretion and became hypertensive unless a daily supplementation of melatonin (30 mg/kg in drinking water) was given [42] . In another study, the melatonin activity on MS induced by a diet containing 60% fructose was examined [43] . This diet increased serum insulin, triglyceride, total cholesterol, free fatty acids, uric acid, leptin, and lipid peroxide concentrations as well as hepatic triglyceride and cholesterol concentrations.
Insulin resistance, relative intra-abdominal fat, and an augmented liver weight were also apparent. The daily intraperitoneal administration of melatonin (1 or 10 mg/kg body weight), starting at 4 weeks of feeding, attenuated all these changes, underlining the efficacy of melatonin in improving a fully developed MS [43] . The present results indicate that the administration of melatonin significantly blunted the body weight and systolic BP increase and normalized glucose tolerance and the circulating lipid and uric acid profile found in two dietinduced models of rodent MS.
At high doses, melatonin can protect against several comorbidities of experimental MS, including diabetes and concomitant oxyradical-mediated damage, inflammation, microvascular disease, and atherothrombotic risk [25, 28, 44] . Indeed, hyperglycemia leads to vascular disease through many intertwined intracellular events linked to oxidative stress. Vascular production of both excessive reactive oxygen species and excessive reactive nitrogen species contribute to endothelial dysfunction by directly damaging macromolecules and activating several cellular stress-sensitive pathways, e.g., nuclear factor κβ, which play a key role in the development of type 1 and type 2 diabetes complications as well as in insulin resistance and impaired insulin secretion occurring in type 2 diabetes [45] . Because melatonin provides both in vivo and in vitro protection at the level of cell membranes, mitochondria, and nucleus due to its free-radical-scavenging and antioxidant properties [44] , the involvement of these mechanisms in melatonin's prevention of vascular sequelae and insulin resistance in the two diet-induced models of rodent MS examined herein seems warranted.
Collectively, the present and previous results are compatible with the view that melatonin can effectively reduce adiposity in several rodent models of hyperadiposity [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] . Remarkably, this effect of melatonin is exerted in the absence of significant differences in food intake. Further exploration is needed to learn the extent to which the weight loss-promoting effect of melatonin is attributable to an increase in energy expenditure by brown adipose tissue (for references, see [56] ).
At the initial phase of MS induced in rats by fructose overload, hypertriglyceridemia and fatty liver without modification or even increase in plasma glucose tolerance to a glucose load have been reported [57, 58] . Recently, we observed in rats at this initial stage of MS similar body weights and a greater tolerance to glucose than controls, together with a significant increase in systolic BP and changes in the circulating lipid profile [59] . The administration of melatonin, although unable to modify the increased tolerance to glucose, was effective normalizing the altered BP and lipid profile found at this early stage of MS. Again, the data support the possible therapeutic role of melatonin in MS, both at initial and established phases.
In the present study, melatonin given simultaneously with a 10% fructose solution or a high-fat diet normalized the abnormally high LH levels but did not affect the inhibited testosterone secretion; rather, it had an inhibitory effect on testosterone when given alone. The results support a lack of effectiveness of melatonin in counteracting the testicular sequelae of rodent MS. Indeed, information has accumulated for decades on the direct inhibitory effect of melatonin on testosterone production in mammalian and nonmammalian testicular tissue [60] [61] [62] [63] . Such an effect of melatonin on circulating testosterone levels appears to be absent in humans [64] [65] [66] [67] [68] .
In the laboratory rat, a number of physiological parameters display seasonal changes even under constant conditions of temperature, lighting, and food availability (for references, see [69] ). Because the administration of melatonin in drinking water is equivalent to exposing the animals to short daily photoperiod in terms of a prolonged duration of melatonin signal [70, 71] , a possible interpretation of the changes in testosterone and LH secretion after melatonin is that they reflect the gonadal inhibition found in the natural environment for wild Rattus norvegicus during winter. In a recent study, it was reported that male rats receiving melatonin in drinking water (3 µg/mL) exhibited a profound inhibitory effect on pituitary PRL gene expression and circulating PRL levels as well as a significant decrease in plasma LH and testosterone concentration [69] .
Hyperuricemia is considered a true cardiovascular and renal risk factor in MS. Hyperuricemia predicts the development of hypertension, diabetes, stroke, and cardiovascular events [72] . Mild hyperuricemia in normal rats induces systemic hypertension, renal vasoconstriction, glomerular hypertension, and hypertrophy as well as tubulointerstitial injury independent of intrarenal crystal formation [73, 74] . Lowering uric acid in fructosefed rats ameliorates much of MS, including a reduction in BP, serum triglycerides, hyperinsulinemia, and weight gain [72] . In the present study, melatonin, besides counteracting the changes in plasma LDL-c, triglyceride, and cholesterol, decreases plasma uric acid levels. This last effect could be of a potential therapeutic value in human MS [72] .
There is considerable evidence that circadian misalignment is associated with increased epidemiological risk for obesity, diabetes, and cardiovascular disease [28, 75] . Lifestyle changes, such as nocturnality and overly rich diets, are followed by a disruption of the sleep/wake cycle and other circadian rhythms. Due to its effects on circadian rhythmicity, melatonin can provide the basis for a therapeutic strategy in MS. Melatonin has been therapeutically used for the treatment of age-related insomnia as well as of other primary and secondary insomnia. A consensus of the British Association for Psychopharmacology on evidence-based treatment of insomnia, parasomnia, and circadian rhythm sleep disorders concluded that melatonin is the first-choice treatment when a hypnotic is indicated in patients older than 55 years [76] .
There are clinical results indicating that type 2 diabetic patients have low levels of circulating melatonin [77] with a concomitant and expected melatonin membrane receptor mRNA expression upregulation [37] . Recently, genomic studies uncovered a link between specific singlenucleotide polymorphisms (SNP) of the melatonin MT 2 receptor (MTNR1B) locus and a prognostic risk of type 2 diabetes [78] [79] [80] . The SNP correlated with higher fasting glucose levels and a pathologically altered insulin secretion responses. These findings strongly bind melatonin to blood glucose homeostasis.
As well as in animal models, clinical studies have shown that melatonin provides benefits on lipid profiles. Melatonin treatment (1 mg/kg for 30 days) elevated HDL-c levels in perimenopausal and postmenopausal women [81] . In an open-label study, which included 33 healthy volunteers and 30 MS patients treated with melatonin, patients with MS had significantly higher values than controls in total cholesterol, LDL-c, triglycerides, systolic and diastolic BP, glycemia, fibrinogen, and erythrocyte thiobarbituric acid-reactive substrate levels [26] . They also had lower levels of HDL-c and reduced activities of catalase, glutathione peroxidase, and superoxide dismutase in erythrocytes. Melatonin (5 mg/day) significantly decreased hypertension and improved the serum lipid profile and antioxidative status [26] . In another open-label study comprising 100 elderly hypertensive patients, the simultaneous application of melatonin together with lisinopril or amlodipine had a normalizing effect on BP and metabolic parameters [82] . Collectively, the results suggest that melatonin therapy can be of benefit for patients with MS, particularly those with arterial hypertension.
It must be noted that melatonin has a high safety profile and is usually remarkably well tolerated. In some studies, melatonin has been administered to patients in very large doses. For example, 300-mg/day doses of melatonin for up to 3 years decreased oxidative stress in patients with amyotrophic lateral sclerosis [83] . Therefore, further studies using melatonin doses in the 50-to 100-mg/day range are needed to clarify its potential therapeutic implications on MS in humans. If one expects melatonin to be an effective cytoprotector, especially in older people, it is likely that the low doses of melatonin used so far are not very beneficial.
